Otenzepad
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Otenzepad is a competitive muscarinic receptor antagonist that is relatively selective at the M2 receptor. It was investigated as a treatment for arrhythmia and bradycardia due to its cardioselectivity but research ceased after stage III clinical trials. The drug was originally developed by the German pharmaceutical company, Boehringer Ingelheim Pharma KG.
Otenzepad is a competitive muscarinic receptor antagonist that is relatively selective at the M2 receptor. It was investigated as a treatment for arrhythmia and bradycardia due to its cardioselectivity but research ceased after stage III clinical trials. The drug was originally developed by the German pharmaceutical company, Boehringer Ingelheim Pharma KG. ==Pharmacodynamics== The (+)-enantiomer has 8 times greater potency at the M2 receptor than the (-)-enantiomer. ==See also== Muscarinic antagonist Antiarrhythmic agent ==References==
Text derived from https://en.wikipedia.org/w/index.php?oldid=1311015198 under CC BY-SA 4.0; modifications have been made.